ESSA Pharma Inc. - Common Stock (OQ:EPIX)

Apr 09, 2024 08:00 am ET
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 2:30 p.m. ET in Toronto, Canada.
Apr 09, 2024 08:00 am ET
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 2:30 p.m. ET in Toronto, Canada.
Mar 07, 2024 07:13 pm ET
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting").
Feb 16, 2024 08:31 am ET
Thinking about buying stock in Adverum Biotechnologies, Roma Green Finance, Wah Fu Education, ESSA Pharma, or Science 37?
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADVM, ROMA, WAFU, EPIX, and SNCE.
Feb 13, 2024 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL
Feb 13, 2024 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL
Feb 06, 2024 07:00 am ET
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 6, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.
Feb 06, 2024 07:00 am ET
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.
Feb 02, 2024 08:31 am ET
Thinking about trading options or stock in General Electric, Taiwan Semiconductor, Shopify, ESSA Pharma, or Snap?
NEW YORK, Feb. 2, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GE, TSM, SHOP, EPIX, and SNAP.
Jan 25, 2024 09:00 am ET
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Jan 25, 2024 09:00 am ET
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Dec 27, 2023 08:31 am ET
Thinking about buying stock in Cingulate, Gracell Biotechnologies, Eli Lilly, ESSA Pharma, or Coherus Biosciences?
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CING, GRCL, LLY, EPIX, and CHRS.
Dec 12, 2023 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023
Dec 12, 2023 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023
Nov 21, 2023 07:00 am ET
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 21, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 12:00 p.m. ET in New York.
Nov 21, 2023 07:00 am ET
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 21, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 12:00 p.m. ET in New York.
Nov 08, 2023 07:00 am ET
ESSA Pharma to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London.
Nov 08, 2023 07:00 am ET
ESSA Pharma to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London.
Nov 06, 2023 04:51 pm ET
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 6, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$50.0 million in aggregate sales proceeds. No offers or sales of com
Nov 06, 2023 04:51 pm ET
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$50.0 million in aggregate sales proceeds. No offers or sales
Oct 26, 2023 05:41 pm ET
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Oct 26, 2023 05:41 pm ET
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Oct 25, 2023 09:31 am ET
Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma?
NEW YORK, Oct. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BITF, INVO, LCID, ESMT, and EPIX.
Oct 24, 2023 09:31 am ET
Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma?
NEW YORK, Oct. 24, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BITF, INVO, LCID, ESMT, and EPIX.
Oct 21, 2023 09:00 am ET
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Oct 21, 2023 09:00 am ET
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Oct 16, 2023 09:31 am ET
Thinking about buying stock in Lithium Americas, AGNC Investment, PCTEL, ESSA Pharma, or Sigma Additive Solutions?
NEW YORK, Oct. 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAC, AGNC, PCTI, EPIX, and SASI.
Sep 18, 2023 07:00 am ET
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD
Sep 18, 2023 07:00 am ET
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD
Aug 31, 2023 07:00 am ET
ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Aug. 31, 2023 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that each of its President and Chief Executive Officer, David R Parkinson and its Executive Vice President and Chief Operating Officer, Peter Virsik (collectively, the "Participants"), have established Automatic Securities Disposition Plans ("ASDPs") in accordance with applicable United States and Canadian securities legislation, in
Aug 08, 2023 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study
Jun 06, 2023 07:00 am ET
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios.
Jun 06, 2023 07:00 am ET
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios.
Jun 01, 2023 07:00 am ET
ESSA Pharma to Present at 2023 Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 1, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time in New York.
Jun 01, 2023 07:00 am ET
ESSA Pharma to Present at 2023 Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 1, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time in New York.
May 11, 2023 07:00 am ET
ESSA Pharma to Present at JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 11, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York.
May 11, 2023 07:00 am ET
ESSA Pharma to Present at JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 11, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York.
May 09, 2023 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023
Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023
May 09, 2023 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023
Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023
Apr 18, 2023 07:00 am ET
ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 18, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2023 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 2:00 p.m. Eastern Time.
Apr 18, 2023 07:00 am ET
ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 18, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2023 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 2:00 p.m. Eastern Time.
Apr 12, 2023 07:00 am ET
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
SOUTH SAN FRANCISCO, Calif., and VANCOUVER, Canada, April 12, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial support agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen") to enable evaluation of ESSA's first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386, in combination with apalutamide as well as the combination of EPI-7386 with abirater
Apr 12, 2023 07:00 am ET
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
SOUTH SAN FRANCISCO, Calif., and VANCOUVER, Canada, April 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial support agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen") to enable evaluation of ESSA's first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386, in combination with apalutamide as well as the combination of EPI-7386 with a
Mar 08, 2023 06:00 am ET
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 8, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 11:20 a.m. Eastern Time.
Mar 08, 2023 06:00 am ET
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 11:20 a.m. Eastern Time.
Feb 13, 2023 04:00 pm ET
ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that further analyses of initial clinical data from two Phase 1 studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer ("mCRPC") will be presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium ("ASCO GU"), taking place February 16-19, 2023, in San Francisco, Cali
Feb 13, 2023 04:00 pm ET
ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that further analyses of initial clinical data from two Phase 1 studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer ("mCRPC") will be presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium ("ASCO GU"), taking place February 16-19, 2023, in San Francisc
Feb 07, 2023 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study
Feb 07, 2023 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study
Feb 02, 2023 03:01 pm ET
ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 2, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will participate in a fireside chat at the Guggenheim Healthcare Talks 5th Annual Oncology Conference in New York City on Thursday, February 9, 2023, at 9:00 a.m. Eastern Time.
Feb 02, 2023 03:01 pm ET
ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 2, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will participate in a fireside chat at the Guggenheim Healthcare Talks 5th Annual Oncology Conference in New York City on Thursday, February 9, 2023, at 9:00 a.m. Eastern Time.
Dec 13, 2022 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022
SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA, Dec. 13, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Dec 13, 2022 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022
SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA, Dec. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Nov 10, 2022 06:00 am ET
ESSA Pharma to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in two upcoming investor conferences.
Nov 10, 2022 06:00 am ET
ESSA Pharma to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in two upcoming investor conferences.
Oct 31, 2022 07:00 am ET
ESSA Provides an Update on its Clinical Collaboration with Janssen
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 31, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Janssen Research and Development ("Janssen") is suspending enrollment into the Phase 1 clinical study of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer ("mCRPC") patients as a result of operational recruitment challenges.  
Oct 31, 2022 07:00 am ET
ESSA Provides an Update on its Clinical Collaboration with Janssen
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 31, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Janssen Research and Development ("Janssen") is suspending enrollment into the Phase 1 clinical study of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer ("mCRPC") patients as a result of operational recruitment challenges.  
Oct 28, 2022 10:39 am ET
Thinking about buying stock in ESSA Pharma, Meta Platforms, Nio, Quanergy Systems, or Alphabet?
NEW YORK, Oct. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EPIX, META, NIO, QNGY, and GOOGL.
Oct 26, 2022 04:01 pm ET
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 26, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data for its lead first generation androgen receptor ("AR") ANITen bAsed Chimera ("ANITAC"™) N-terminal domain ("NTD") degrader in a poster session at the 34th EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
Oct 26, 2022 04:01 pm ET
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data for its lead first generation androgen receptor ("AR") ANITen bAsed Chimera ("ANITAC"™) N-terminal domain ("NTD") degrader in a poster session at the 34th EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
Oct 26, 2022 07:00 am ET
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and durable prostate specific antigen ("PSA") reductions observed in five of six patients
Oct 26, 2022 07:00 am ET
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and durable prostate specific antigen ("PSA") reductions observed in five of six patients
Sep 13, 2022 07:00 am ET
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Sept. 13, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors. Dr. Kantoff brings invaluable insight and experience to ESSA as a renowned medical oncologist and leader in the clinical development of new prostate cancer treatments.
Sep 13, 2022 07:00 am ET
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors. Dr. Kantoff brings invaluable insight and experience to ESSA as a renowned medical oncologist and leader in the clinical development of new prostate cancer treatments.
Aug 04, 2022 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 4, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Aug 04, 2022 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Jun 30, 2022 06:21 pm ET
ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada,, June 30, 2022 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that each of its President and Chief Executive Officer, David R Parkinson and its Executive Vice President and Chief Operating Officer, Peter Virsik (collectively, the "Participants"), have established Automatic Securities Disposition Plans ("ASDPs") in accordance with applicable United States and Canadian securities legislatio
Jun 27, 2022 04:01 pm ET
ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development
EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important efficacy signals
Jun 27, 2022 04:01 pm ET
ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development
EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important efficacy signals
Jun 02, 2022 07:00 am ET
ESSA Pharma to Present at 2022 Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 2, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 3:00 p.m. Eastern Time.  
Jun 02, 2022 07:00 am ET
ESSA Pharma to Present at 2022 Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 2, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 3:00 p.m. Eastern Time.  
May 10, 2022 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
May 10, 2022 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Apr 26, 2022 04:30 pm ET
ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 26, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 2:30 p.m. Eastern Time.
Apr 26, 2022 04:30 pm ET
ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 2:30 p.m. Eastern Time.
Apr 08, 2022 01:00 pm ET
ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders
Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients
Apr 08, 2022 01:00 pm ET
ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders
Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients
Mar 10, 2022 03:05 pm ET
ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference
South San Francisco, California and Vancouver, Canada, March 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 2:40 p.m. Eastern Time.
Mar 10, 2022 03:05 pm ET
ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference
South San Francisco, California and Vancouver, Canada, March 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 2:40 p.m. Eastern Time.
Mar 09, 2022 10:34 pm ET
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 9, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 9, 2022 (the "Meeting").
Mar 09, 2022 10:34 pm ET
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 9, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 9, 2022 (the "Meeting").
Mar 08, 2022 03:30 pm ET
ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting
First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders
Mar 08, 2022 03:30 pm ET
ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting
First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders
Feb 03, 2022 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021
HOUSTON, Texas and VANCOUVER, Canada, Feb. 3, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Jan 19, 2022 06:00 am ET
ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Jan. 19, 2022 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA's lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas Pharma Inc.'s ("Astellas") and Pfizer Inc.'s ligand-binding domain androgen receptor in
Jan 19, 2022 06:00 am ET
ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Jan. 19, 2022 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA's lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas Pharma Inc.'s ("Astellas") and Pfizer Inc.'s ligand-binding domain androgen receptor inhibitor
Nov 18, 2021 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021
VANCOUVER, Canada and HOUSTON, Texas, Nov. 18, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Nov 18, 2021 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021
VANCOUVER, Canada and HOUSTON, Texas, Nov. 18, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Nov 08, 2021 06:00 am ET
ESSA Pharma to Participate in Three Upcoming Investor Conferences
VANCOUVER, Canada and HOUSTON, Texas, Nov. 8, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings at three upcoming virtual investor conferences. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be participating in the one-on-one meetings.
Nov 08, 2021 06:00 am ET
ESSA Pharma to Participate in Three Upcoming Investor Conferences
VANCOUVER, Canada and HOUSTON, Texas, Nov. 8, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings at three upcoming virtual investor conferences. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be participating in the one-on-one meetings.
Oct 28, 2021 04:05 pm ET
ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat
VANCOUVER, Canada and HOUSTON, Texas, Oct. 28, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data characterizing the mechanism of action of EPI-7386, ESSA's lead product candidate for the treatment of prostate cancer. Data were presented in a poster format at the 2021 Prostate Cancer Foundation (PCF) Scientific Retreat, taking place virtually October 28-29, 2021.
Oct 28, 2021 04:05 pm ET
ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat
VANCOUVER, Canada and HOUSTON, Texas, Oct. 28, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data characterizing the mechanism of action of EPI-7386, ESSA's lead product candidate for the treatment of prostate cancer. Data were presented in a poster format at the 2021 Prostate Cancer Foundation (PCF) Scientific Retreat, taking place virtually October 28-29, 2021.
Oct 07, 2021 09:00 am ET
ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386
-       Data presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics –
Oct 07, 2021 09:00 am ET
ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386
-       Data presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics –
Oct 07, 2021 06:30 am ET
Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration
IRVING, Texas, and HOUSTON, and VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ -- Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, and ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today a Precision Development program to support ESSA's ongoing clinical development of EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer ("mCR
Aug 31, 2021 04:05 pm ET
ESSA Pharma to Present at Upcoming September Investor Conferences
VANCOUVER, Canada and HOUSTON, Texas, Aug. 31, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at two upcoming virtual investor conferences. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be available for one-on-one meetings.
Aug 31, 2021 04:05 pm ET
ESSA Pharma to Present at Upcoming September Investor Conferences
VANCOUVER, Canada and HOUSTON, Texas, Aug. 31, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at two upcoming virtual investor conferences. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be available for one-on-one meetings.
Aug 16, 2021 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021
HOUSTON, Texas and VANCOUVER, Canada, Aug. 16, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Aug 16, 2021 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021
HOUSTON, Texas and VANCOUVER, Canada, Aug. 16, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
May 25, 2021 07:00 am ET
ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference
HOUSTON, Texas and VANCOUVER, Canada, May 25, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr. David R. Parkinson, Chief Executive Officer of ESSA, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference. Dr. Parkinson, along with Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will be available for one-on-one meetings. The conference will take pl
May 06, 2021 07:01 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021
- Presented promising preliminary pharmacokinetic and clinical data on EPI-7386 in metastatic castration-resistant prostate cancer at 2021 AACR - Raised approximately $150 million in a public offering
Apr 28, 2021 07:00 am ET
ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON, Texas and VANCOUVER, Canada, April 28, 2021 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial collaboration and supply agreement with Bayer to evaluate ESSA's lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Bayer's androgen receptor inhibitor, darolutamide, in patients with metastatic castration-resistant prostate can
Apr 14, 2021 07:00 am ET
ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference
HOUSTON, Texas and VANCOUVER, Canada, April 14, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr. David R. Parkinson, Chief Executive Officer of ESSA Pharma, will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference, taking place virtually April 20-21, 2021. Dr. Parkinson, along with Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be available
Apr 10, 2021 08:30 am ET
ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting
HOUSTON, Texas and VANCOUVER, Canada, April 10, 2021 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead product candidate, EPI-7386, at the 2021 American Association of Cancer Research (AACR) Annual Meeting, which is taking place virtually April 10-15, 2021. EPI-7386 is an investigational, highly selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor, which exhibits
Mar 26, 2021 04:05 pm ET
ESSA Announces Change to its Board of Directors
HOUSTON, Texas and VANCOUVER, BC, March 26, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Ari Brettman, M.D., has stepped down from ESSA's Board of Directors, which he has been a member of since 2019. Dr. Brettman is a Managing Director of Blackstone's Life Science Group and will be assuming more responsibilities in this role.
Mar 04, 2021 10:32 am ET
ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing
VANCOUVER, BC and HOUSTON, March 4, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the underwriters have exercised their option (the "Option") to purchase an additional 724,637 common shares in the capital of the Company (the "Common Shares"), in connection with the Company's recently completed underwritten public offering of 4,830,918 Common Shares, which closed on February 22, 2021 (the "Offering"). On closing of the Option, the
Feb 25, 2021 05:33 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on February 25, 2021 (the "Meeting").
Feb 25, 2021 05:33 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on February 25, 2021 (the "Meeting").
Feb 25, 2021 03:30 pm ET
ESSA Pharma to Present at Upcoming March Investor Conferences
HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr. David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at three upcoming virtual investor conferences. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be available for one-on-one meetings.
Feb 25, 2021 03:30 pm ET
ESSA Pharma to Present at Upcoming March Investor Conferences
HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr. David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at three upcoming virtual investor conferences. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be available for one-on-one meeting
Feb 25, 2021 06:00 am ET
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical collaboration and supply agreement with Astellas Pharma Inc. ("Astellas") to evaluate ESSA's lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas and Pfizer Inc.'s androgen receptor inhibitor, enzalutamide, in patients with meta
Feb 25, 2021 06:00 am ET
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical collaboration and supply agreement with Astellas Pharma Inc. ("Astellas") to evaluate ESSA's lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas and Pfizer Inc.'s androgen receptor inhibitor, enzalutamide, in patients wi
Feb 22, 2021 10:48 am ET
ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock
VANCOUVER, BC and HOUSTON, Feb. 22, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 4,830,918 of its common shares at a public offering price of $27.00 per share before underwriting discounts (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 724,637 common shares. The gross proceeds from the Offering were approximately $130 million.
Feb 22, 2021 10:48 am ET
ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock
VANCOUVER, BC and HOUSTON, Feb. 22, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 4,830,918 of its common shares at a public offering price of $27.00 per share before underwriting discounts (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 724,637 common shares. The gross proceeds from the Offering were approximately $130 million.
Feb 17, 2021 09:47 pm ET
ESSA Pharma Announces Pricing of Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, Feb. 17, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 4,830,918 common shares at a public offering price of $27.00 per share, before underwriting discounts, for an aggregate offering of approximately $130.4 million (the "Offering"). ESSA has granted the underwriters a 30-day option to purchase, in whole or in part, up to an additional 724,637 shares of its co
Feb 17, 2021 09:47 pm ET
ESSA Pharma Announces Pricing of Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, Feb. 17, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 4,830,918 common shares at a public offering price of $27.00 per share, before underwriting discounts, for an aggregate offering of approximately $130.4 million (the "Offering"). ESSA has granted the underwriters a 30-day option to purchase, in whole or in part, up to an additional 724,637 shares of
Feb 16, 2021 03:01 pm ET
ESSA Pharma Announces Proposed Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, Feb. 16, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has commenced an underwritten public offering of up to $100,000,000 of its common shares (the "Offering"). ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. In connection with the
Feb 16, 2021 03:01 pm ET
ESSA Pharma Announces Proposed Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, Feb. 16, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has commenced an underwritten public offering of up to $100,000,000 of its common shares (the "Offering"). ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. In connection wi
Feb 11, 2021 07:02 am ET
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today will present preclinical and clinical pharmacology data from ESSA's Phase 1 clinical trial of EPI-7386 for the treatment of patients with metastatic castration-resistant prostate cancer ("mCRPC") at the 2021 American Society of Clinical Oncology Genitourinary ("ASCO GU") Cancers Symposium. EPI-7386, ESSA's lead product candidate, is an investigational, highly-selec
Feb 11, 2021 07:02 am ET
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today will present preclinical and clinical pharmacology data from ESSA's Phase 1 clinical trial of EPI-7386 for the treatment of patients with metastatic castration-resistant prostate cancer ("mCRPC") at the 2021 American Society of Clinical Oncology Genitourinary ("ASCO GU") Cancers Symposium. EPI-7386, ESSA's lead product candidate, is an investigational, highl
Feb 11, 2021 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020
VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Feb 11, 2021 06:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020
VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Jan 13, 2021 06:00 am ET
ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Jan. 13, 2021 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical collaboration and supply agreement with Janssen Research & Development, LLC (Janssen) to evaluate ESSA's first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386, in combination with apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients with met
Jan 13, 2021 06:00 am ET
ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Jan. 13, 2021 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical collaboration and supply agreement with Janssen Research & Development, LLC (Janssen) to evaluate ESSA's first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386, in combination with apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients w
Dec 15, 2020 04:01 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
VANCOUVER and HOUSTON, Dec. 15, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Dec 15, 2020 04:01 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
VANCOUVER and HOUSTON, Dec. 15, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Nov 25, 2020 06:00 am ET
ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference
HOUSTON and VANCOUVER, BC, Nov. 25, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Evercore ISI 3rd Annual HealthCONx Conference.
Nov 25, 2020 06:00 am ET
ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference
HOUSTON and VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Evercore ISI 3rd Annual HealthCONx Conference.
Nov 10, 2020 06:00 am ET
ESSA Pharma to Participate in Upcoming Investor Conferences
HOUSTON and VANCOUVER, BC, Nov. 10, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Stifel 2020 Virtual Healthcare Conference and Jefferies Virtual London Healthcare Conference.
Nov 10, 2020 06:00 am ET
ESSA Pharma to Participate in Upcoming Investor Conferences
HOUSTON and VANCOUVER, BC, Nov. 10, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Stifel 2020 Virtual Healthcare Conference and Jefferies Virtual London Healthcare Conference.
Oct 26, 2020 05:01 pm ET
ESSA Pharma Inc. Announces Delisting from the TSX-V
HOUSTON and VANCOUVER, BC, Oct. 26, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today its intention to voluntarily delist all of its issued and outstanding common shares (the "Shares"), currently listed under symbol "EPI", from the TSX Venture Exchange (the "TSX-V"), which is currently anticipated to occur on or about October 30, 2020.
Oct 26, 2020 05:01 pm ET
ESSA Pharma Inc. Announces Delisting from the TSX-V
HOUSTON and VANCOUVER, BC, Oct. 26, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today its intention to voluntarily delist all of its issued and outstanding common shares (the "Shares"), currently listed under symbol "EPI", from the TSX Venture Exchange (the "TSX-V"), which is currently anticipated to occur on or about October 30, 2020.
Oct 24, 2020 07:18 pm ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium
HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics ("ENA").
Oct 24, 2020 07:18 pm ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium
HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics ("ENA").
Oct 19, 2020 07:00 am ET
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
HOUSTON, Texas and VANCOUVER, BC, Oct. 19, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that several abstracts on ESSA's clinical candidate, EPI-7386, have been selected for presentation at upcoming medical and scientific symposia. These presentations will provide further preclinical characterization of EPI-7386.
Oct 19, 2020 07:00 am ET
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
HOUSTON, Texas and VANCOUVER, BC, Oct. 19, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that several abstracts on ESSA's clinical candidate, EPI-7386, have been selected for presentation at upcoming medical and scientific symposia. These presentations will provide further preclinical characterization of EPI-7386.
Sep 21, 2020 07:00 am ET
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd at 11:40am Eastern
Sep 17, 2020 05:05 pm ET
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
HOUSTON and VANCOUVER, BC, Sept. 17, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of data of ESSA's clinical candidate, EPI-7386, at the ESMO Virtual Congress 2020. 
Sep 14, 2020 07:00 am ET
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Sept. 14, 2020 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX) (TSXV: EPI) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer today announced that the U.S. Food and Drug Administration ("FDA") granted Fast Track Designation to EPI-7386, its oral and highly-selective N-terminal domain inhibitor of the androgen receptor, for the treatment of adult male patients with metastatic castration-resistant prostate cancer ("mCRPC") resistant to standard-of-care treatment.
Sep 10, 2020 07:00 am ET
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
HOUSTON and VANCOUVER, BC, Sept. 10, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 and at the Cantor Fitzgerald Global Healthcare Conference 2020 on Thursday September 17, 2020.
Aug 06, 2020 08:00 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020
VANCOUVER, BC and HOUSTON, Aug. 6, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Aug 06, 2020 08:00 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020
VANCOUVER, BC and HOUSTON, Aug. 6, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Jul 31, 2020 10:16 am ET
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000
HOUSTON and VANCOUVER, BC, July 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 1,065,000 common sha
Jul 31, 2020 10:16 am ET
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000
HOUSTON and VANCOUVER, BC, July 31, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 1,065,000 com
Jul 28, 2020 09:18 pm ET
ESSA Pharma Announces Pricing of Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, July 28, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 7,100,000 common shares at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA has granted the underwriters a 30-day option to purchase, in whole or in part, up to an additional 1,065,000
Jul 28, 2020 09:18 pm ET
ESSA Pharma Announces Pricing of Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, July 28, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 7,100,000 common shares at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA has granted the underwriters a 30-day option to purchase, in whole or in part, up to an additional 1,
Jul 28, 2020 04:01 pm ET
ESSA Pharma Announces Proposed Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, July 28, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has commenced an underwritten public offering of its common shares (the "Offering"). ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. In connection with the Offering,
Jul 28, 2020 04:01 pm ET
ESSA Pharma Announces Proposed Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, July 28, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has commenced an underwritten public offering of its common shares (the "Offering"). ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. In connection with the Off
Jul 15, 2020 07:00 am ET
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
HOUSTON and VANCOUVER, BC, July 15, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in a Phase 1 clinical trial designed to demonstrate the safety and tolerability of EPI-7386 in metastatic castration-resistant prostate cancer ("mCRPC") patients who failed standard of care treatments, including second generation anti-androgens.  EPI-7386 is a small molecule inhibitor of the N-terminal domain of the androgen receptor (AR) which h
Jul 15, 2020 07:00 am ET
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
HOUSTON and VANCOUVER, BC, July 15, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in a Phase 1 clinical trial designed to demonstrate the safety and tolerability of EPI-7386 in metastatic castration-resistant prostate cancer ("mCRPC") patients who failed standard of care treatments, including second generation anti-androgens.  EPI-7386 is a small molecule inhibitor of the N-terminal domain of the androgen receptor (AR)
Jun 22, 2020 07:30 am ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
HOUSTON and VANCOUVER, BC, June 22, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX); (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 American Association for Cancer Research ("AACR") Virtual Annual Meeting II. 
Jun 22, 2020 07:30 am ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
HOUSTON and VANCOUVER, BC, June 22, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX); (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 American Association for Cancer Research ("AACR") Virtual Annual Meeting II. 
May 27, 2020 07:00 am ET
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
HOUSTON and VANCOUVER, May 27, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Jefferies Virtual Healthcare Conference on Thursday June 4, 2020 at 3:30pm Eastern.
May 27, 2020 07:00 am ET
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
HOUSTON and VANCOUVER, May 27, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Jefferies Virtual Healthcare Conference on Thursday June 4, 2020 at 3:30pm Eastern.
May 15, 2020 07:30 am ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
HOUSTON and VANCOUVER, May 15, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 Virtual American Urological Association ("AUA") Annual  Meeting.
May 15, 2020 07:30 am ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
HOUSTON and VANCOUVER, May 15, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 Virtual American Urological Association ("AUA") Annual  Meeting.
May 07, 2020 05:05 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
VANCOUVER and HOUSTON, May 7, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
May 07, 2020 05:05 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
VANCOUVER and HOUSTON, May 7, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Apr 30, 2020 05:45 pm ET
ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
VANCOUVER and HOUSTON, April 30, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the U.S. Food and Drug Administration ("FDA") has notified the Company that it may proceed with its proposed clinical investigation of EPI-7386 for the treatment of metastatic castration-resistant prostate cancer ("mCRPC"). ESSA previously announced on March 30th, 2020 that it had filed an Investigational New Drug ("IND") application for EPI-7386 with the
Apr 30, 2020 05:45 pm ET
ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
VANCOUVER and HOUSTON, April 30, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the U.S. Food and Drug Administration ("FDA") has notified the Company that it may proceed with its proposed clinical investigation of EPI-7386 for the treatment of metastatic castration-resistant prostate cancer ("mCRPC"). ESSA previously announced on March 30th, 2020 that it had filed an Investigational New Drug ("IND") application for EPI-7386 wi
Apr 13, 2020 06:08 pm ET
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
VANCOUVER and HOUSTON, April 13, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of April 13, 2020. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$35.0 million in aggregate sales proceeds in "at-the-market" transactions. No offers or sales of common
Apr 13, 2020 06:08 pm ET
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
VANCOUVER and HOUSTON, April 13, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of April 13, 2020. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$35.0 million in aggregate sales proceeds in "at-the-market" transactions. No offers or sales of
Mar 31, 2020 07:00 am ET
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
VANCOUVER and HOUSTON, March 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Mar 31, 2020 07:00 am ET
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
VANCOUVER and HOUSTON, March 31, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Mar 24, 2020 04:00 pm ET
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences industry. At the event, management teams will present a business overview and highlights using an online, digital meeting format.
Feb 27, 2020 06:51 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON and VANCOUVER, Feb. 27, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on February 27, 2020 in Vancouver, British Columbia, Canada (the "Meeting").
Feb 13, 2020 04:48 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
VANCOUVER and HOUSTON, TX, Feb. 13, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Feb 10, 2020 05:15 pm ET
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
HOUSTON and VANCOUVER, Feb. 10, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that several abstracts on ESSA's lead clinical candidate, EPI-7386, have been selected for presentation at upcoming medical and scientific symposia. These presentations will provide further preclinical characterization of EPI-7386 including new preclinical data regarding safety studies, gene expression and combination data with antiandrogens.
Dec 19, 2019 04:15 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
VANCOUVER and HOUSTON, Dec. 19, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Dec 12, 2019 11:35 am ET
Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors
Janpix, Inc., a privately-held biopharmaceutical company dedicated to the discovery and development of inhibitors/degraders of Signal Transducer & Activator of Transcription (STAT) proteins for oncological indications, announced today the...
Nov 11, 2019 09:00 am ET
Encode Ideas, L.P. Announces the Initiation of Research Coverage on ESSA Pharma, Inc.
Dover, Delaware--(Newsfile Corp. - November 11, 2019) - Encode Ideas, L.P. Initiates Research on ESSA Pharma, Inc. (NASDAQ: EPIX). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:
Oct 30, 2019 06:00 am ET
ESSA Pharma Grants Stock Options
HOUSTON and VANCOUVER, Oct. 30, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation (the "Common shares").  The stock options will vest in 36 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date. The stock options are exercisable on or before October 30, 2029 a
Oct 30, 2019 06:00 am ET
ESSA Pharma Grants Stock Options
HOUSTON and VANCOUVER, Oct. 30, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation (the "Common shares").  The stock options will vest in 36 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date. The stock options are exercisable on or before October 30,
Oct 28, 2019 07:30 am ET
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
HOUSTON and VANCOUVER, Oct. 28, 2019 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today in Boston will present new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Oct 28, 2019 07:30 am ET
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
HOUSTON and VANCOUVER, Oct. 28, 2019 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today in Boston will present new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Oct 18, 2019 04:15 pm ET
ESSA Announces Changes to its Board of Directors
VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The Company also announces that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments.  
Oct 18, 2019 04:15 pm ET
ESSA Announces Changes to its Board of Directors
VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The Company also announces that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments.  
Oct 07, 2019 02:04 pm ET
ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants
VANCOUVER and HOUSTON, Oct. 7, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that, pursuant to the Company's existing stock option plan (the "Existing Option Plan"), it has granted incentive stock options ("Options") to certain directors, officers, employees and consultants of the Company to purchase up to an aggregate of 1,441,530 common shares in the capital of the Company (the "Common Shares"). A total of 1,186,530 of such Options will
Oct 07, 2019 02:04 pm ET
ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants
VANCOUVER and HOUSTON, Oct. 7, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that, pursuant to the Company's existing stock option plan (the "Existing Option Plan"), it has granted incentive stock options ("Options") to certain directors, officers, employees and consultants of the Company to purchase up to an aggregate of 1,441,530 common shares in the capital of the Company (the "Common Shares"). A total of 1,186,530 of such Optio
Sep 28, 2019 07:29 am ET
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
HOUSTON and VANCOUVER, Sept. 28, 2019 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting.
Sep 28, 2019 07:29 am ET
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
HOUSTON and VANCOUVER, Sept. 28, 2019 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting.
Sep 19, 2019 07:30 am ET
ESSA to Present at Ladenburg Thalmann Healthcare Conference
HOUSTON and VANCOUVER, Sept. 19, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Ladenburg Thalmann Helathcare Conference on Tuesday September 24, 2019 at 9:30am EDT at the Sofitel New York City in New York.
Sep 19, 2019 07:30 am ET
ESSA to Present at Ladenburg Thalmann Healthcare Conference
HOUSTON and VANCOUVER, Sept. 19, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Ladenburg Thalmann Helathcare Conference on Tuesday September 24, 2019 at 9:30am EDT at the Sofitel New York City in New York.
Sep 05, 2019 07:00 am ET
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
HOUSTON and VANCOUVER, Sept. 5, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference on Monday September 9, 2019 at 5:05pm EDT  at the Lotte New York Palace Hotel in New York.
Sep 05, 2019 07:00 am ET
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
HOUSTON and VANCOUVER, Sept. 5, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference on Monday September 9, 2019 at 5:05pm EDT  at the Lotte New York Palace Hotel in New York.
Aug 27, 2019 09:21 am ET
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
VANCOUVER and HOUSTON, Aug. 27, 2019 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to its previously announced equity offering, it has closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States for aggregate gross proceeds of US$36 million (the "Offering"). The Offering was led by Soleus Capital and included RA Capital Management as a ne
Aug 27, 2019 09:21 am ET
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
VANCOUVER and HOUSTON, Aug. 27, 2019 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to its previously announced equity offering, it has closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States for aggregate gross proceeds of US$36 million (the "Offering"). The Offering was led by Soleus Capital and included RA Capital Management
Aug 23, 2019 10:37 am ET
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
VANCOUVER and HOUSTON, Aug. 23, 2019 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the "Offering"). The Offering is being led by Soleus Capital and includes RA Capital Management as a new investor. Existing investors, including BVF Partners LP, among others, are also co-investing in the Offering.
Aug 23, 2019 10:37 am ET
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
VANCOUVER and HOUSTON, Aug. 23, 2019 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the "Offering"). The Offering is being led by Soleus Capital and includes RA Capital Management as a new investor. Existing investors, including BVF Partners LP, among others, are also co-investing in the Offer
Aug 14, 2019 07:30 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019
VANCOUVER and HOUSTON, Aug. 14, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Aug 14, 2019 07:30 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019
VANCOUVER and HOUSTON, Aug. 14, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Jul 31, 2019 04:45 am ET
ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective
VANCOUVER and HOUSTON, July 31, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019, the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme") has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc ("Realm").
Jul 31, 2019 04:45 am ET
ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective
VANCOUVER and HOUSTON, July 31, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019, the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme") has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc ("Realm").
Jul 30, 2019 02:15 am ET
ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics
VANCOUVER and HOUSTON, TX, July 30, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 8, 2019, the High Court of Justice in England and Wales has today sanctioned the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm").
Jul 30, 2019 02:15 am ET
ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics
VANCOUVER and HOUSTON, TX, July 30, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 8, 2019, the High Court of Justice in England and Wales has today sanctioned the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm").
Jul 15, 2019 07:30 am ET
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
VANCOUVER and HOUSTON, July 15, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer ("CMO").  With over 25 years of drug development, regulatory and medical affairs activities, Dr. Cesano will provide leadership in advancing the Company's lead clinical candidate, EPI-7386 into Phase 1 clinical testing.
Jul 15, 2019 07:30 am ET
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
VANCOUVER and HOUSTON, July 15, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer ("CMO").  With over 25 years of drug development, regulatory and medical affairs activities, Dr. Cesano will provide leadership in advancing the Company's lead clinical candidate, EPI-7386 into Phase 1 clinical testing.
Jul 08, 2019 03:39 pm ET
ESSA Provides Update on Court Hearing
VANCOUVER and HOUSTON, July 8, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that the hearing at the High Court of Justice in England and Wales (the "Court") in respect of the proposed scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm"), took place today in London.
Jul 08, 2019 03:39 pm ET
ESSA Provides Update on Court Hearing
VANCOUVER and HOUSTON, July 8, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that the hearing at the High Court of Justice in England and Wales (the "Court") in respect of the proposed scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm"), took place today in London.
Jun 26, 2019 06:08 pm ET
ESSA Provides an Update to the Acquisition of Realm Therapeutics
HOUSTON and VANCOUVER, June 26, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer provides an update, further to the announcement made on May 16, 2019 announcing the acquisition of Realm Therapeutics plc ("Realm") by ESSA pursuant to a scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme").  The Court Meeting and General Meeting in relation to the Scheme were each held by Realm on June 24, 2019 in London, United Kingdom and all resol

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More